[123 Pages Report] The overall market for clinical trial imaging is projected to reach $1069.7 billion by 2021 from $773.4 billion in 2016, at a CAGR of 6.7% from 2016 to 2021. Increase in R&D spending by growing pharmaceutical and biotechnology industries is attributed to the growth of the market.

Objectives of the Study

To define, describe, and segment the global market of clinical trial imaging on the basis of product and service, modality, end user, and region

To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and industry-specific challenges)

To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the global market

To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market players

To forecast the size of the market segments with respect to four major regional segments, namely, North America, Europe, Asia, and the Rest of the World (RoW)

To profile the key players in the market and comprehensively analyze their market positions and core competencies

To track and analyze competitive developments such as acquisitions, product launches, expansions, regulatory approvals, and agreements in the market

Research Methodology

Both, top-down and bottom-up approaches were used to validate the size of the global market of clinical trial imaging and estimate the size of various other dependent submarkets. Major players in the market were identified through secondary research and their market presence was studied through primary and secondary research. Secondary research included the study of the annual and financial reports of top market players, presentations, websites, and press releases of top players, news articles, journals; and paid databases ,white papers, medical journals, certified publications, articles from recognized authors, directories, and databases such as American College of Radiology (ACR), American Medical Association (AMA), Digital Imaging and Communication in Medicine (DICOM), European Association of Nuclear Medicine (EANM), International Consortium for Medical Imaging Technology (ICMIT), North American Society for Cardiovascular Imaging (NASCI), National Cancer Institute (NCI), Society of Nuclear Medicine and Molecular Imaging (SNMMI). Whereas, primary research included extensive interviews with key opinion leaders such as CEOs, vice presidents, directors, marketing executives, and related key executives from various companies. The percentage splits, shares, and breakdowns of the segments were determined using secondary sources and verified through primary sources. This data is consolidated and added to detailed inputs and analysis from MarketsandMarkets and presented in this report.

To know about the assumptions considered for the study, download the pdf brochure

Target Audience:

Medical Device Industries

Academic and Government Research Institutes

Diagnostic Centers

Market Research and consulting firms

Pharmaceutical and biotechnology manufacturers

Contract research organizations (CROs)

Contract manufacturing organizations (CMOs)

Clinical Trial Imaging Manufacturers, Vendors, and Distributors

Scope of the Report

The research report categorizes the global market of clinical trial imaging into the following segments and subsegments:

By Product and Service

Services

Software

By Modality

Computed Tomography

Magnetic Resonance Imaging

Positron Emission Tomography

Ultrasound

X-Ray

Echocardiography

Other Modalities (Magnetic Resonance Elastography and Dual-energy x-ray Absorptiometry)

By End User

Pharmaceutical Companies

Biotechnology Companies

Medical Device Manufacturers

Contract Research Organizations

Academic and Government Research Institutes

Other End Users (Cosmetics & skin care industries)

By Region

North America US Canada

Europe

Asia

Rest of the World (RoW)

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company�s specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to 5)

Geographic Analysis

Detailed analysis of market in European countries such as the UK, Germany, France, Italy, Spain, and others

Detailed analysis of market in Asia Pacific countries such as China, Japan, India, and others

The global market is projected to reach $1069.7 billion by 2021 from $773.4 billion in 2016, at a CAGR of 6.7% from 2016 to 2021. Clinical trial imaging is used to create images of the human body for clinical purposes to reveal, diagnose, or examine diseases. Imaging testing is mainly done using X-rays, computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, positron emission tomography (PET), and echocardiography (ECHO). In clinical trial, imaging is used primarily to evaluate efficacy end-points and more frequently, for safety evaluations and/or eligibility criteria. Growth in this market will largely be driven by the increase in R&D spending and growth in the pharmaceutical and biotechnology industries and the increasing number of contract research organizations.

In this report, the global market is broadly segmented by product and service, modality, end user, and region.

The global market is broadly segmented into service and software. The services segment is expected to hold the largest share of the market in 2016, and grow at the highest CAGR during the forecast period. Growth in this segment can be attributed to the increased outsourcing of imaging clinical trials by pharmaceutical, biotechnology, and medical device companies to CROs will drive the growth of the services segment.

Based on the modality, the market is segmented into CT, MRI, PET, ultrasound, ECHO, x-ray, and other modalities (such as magnetic resonance elastography (MRE) and dual-energy X-ray absorptiometry (DXA)). The positron emission tomography (PET) segment is expected to grow at the highest CAGR during the forecast period. Growth in this segment can be attributed to the increasing usage of PET in clinical trials for screening various organs to obtain information about the function and metabolism.

On the basis of end user, the market is categorized into pharmaceutical companies, biotechnology companies, medical device manufacturers, contract research organizations, academic and government research institutes, and other end users (cosmetics and skin care companies). Medical device manufacturers segment is expected to grow at a highest CAGR during the forecast period. Increased R&D spending by medical device manufacturers and the growing medical devices market are factors contributing to the high growth of this end-user segment

Geographically, the market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). Asia is expected to grow at the highest CAGR in the forecast period. The growth in the Asian clinical trial imaging market is driven by the growth in pharmaceutical & biotechnology industries and increase in R&D spending in the region.

However, high competition among major players, which acts as an entry barrier for new entrants, and high implementation costs of imaging systems are restraining the growth of this market.

The key players in the global clinical trial imaging market are BioClinica, Inc. (U.S.), Biomedical Systems (U.S.), Cardiovascular Imaging Technologies (U.S.), ICON Public Limited Company (Ireland), Intrinsic Imaging, LLC (U.S.), IXICO, PLC (U.K.), PAREXEL International Corporation (U.S.), Radiant Sage, LLC (U.S.), BioTelemetric, Inc. (U.S.), and WorldCare Clinical, LLC (U.S.). These players focus on inorganic and organic strategies such as greements, collaborations, and partnerships, expansions, acquisitions to sustain their growth in the global market.

To speak to our analyst for a discussion on the above findings, click Speak to Analyst